Hypocalcemia is the occurs when serum calcium concentration is below the lower limit of normal range.
Acute hypocalcemia has neuromuscular tetany as hallmark symptom. Patients have rapid decrease in serum calcium and present with symptomatic hypocalcemia.
It is an emergency condition and requires immediate attention. Ca (IV) should be administered until signs and symptoms abate or until serum Ca levels rise.
Chronic hypocalcemia has asymptomatic mild hypocalcemia. Treatment is necessary to avoid long term complications. Oral Ca may be administered.
The incidence of denosumab-related hypocalcaemia in postmenopausal women with osteoporosis appears to be higher in real-life clinical settings than what is reported in clinical trials. However, a protocol that requires assessment and replacement of vitamin D, calcium and creatinine levels in all patients prescribed denosumab lowers the incidence, according to a study presented at the 6th Asia-Pacific Osteoporosis Meeting (IOF Regionals 2016) in Singapore.
Loaded calcitriol therapy manages hypocalcaemia in the first 7 days after parathyroidectomy for chronic kidney diseases compared with titrated calcitriol and control, as shown in a randomised control, open labeled study.
In this article, the path of hypocalcemia during the first days of critical illness was established in terms of mortality. The role of calcium supplementation on calcium normalization and mortality was assessed as well.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Endocrinology - Malaysia digital copy today!
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.